The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Healios Poised to Go into the Black with Sakigake-Designated MultiStem, Revs Up Universal Cell Biz
December 10, 2019
-
REGULATORY Metformin Manufacturers Ordered to Test for Potential Carcinogen Contamination
December 10, 2019
-
REGULATORY Pharma Industry Might Accept Comparator PMP Deduction If No Eligible Use Added in 6 Years
December 9, 2019
-
REGULATORY Big 4 Wholesalers Faced Wrath of FTC for Allocating Priority Drug Categories before Bidding
December 6, 2019
-
COMMENTARY Course of Govt’s “All-Generation” Social Security Reform Could Impact Pharma
December 5, 2019
-
REGULATORY Average NHI-Market Price Gap at 8.0%, Suspected Bid-Rigging Data Excluded: Chuikyo
December 4, 2019
-
BUSINESS With Audentes Buyout, Astellas Poised to Position “Genetic Regulation” as 5th Biz Pillar
December 4, 2019
-
BUSINESS Astellas to Buy Gene Therapy Player Audentes for US$3 Billion
December 3, 2019
-
REGULATORY Causal Link between Eisai’s Epilepsy Drug and Trial Death Can’t Be Ruled Out: MHLW
December 2, 2019
-
BUSINESS Stakeholders Rap Big 4 Wholesalers for Bid-Rigging Charges, Say Scandal Shutters Trust in Drug Price Surveys
November 29, 2019
-
BUSINESS 10-Plus Japan Drug Makers Up FY2019 Guidance on Bullish New Drugs, Mainstays: Tally
November 29, 2019
-
REGULATORY Amended PMD Law Set for 3-Step Enforcement, 1st Execution Eyed Next Autumn
November 28, 2019
-
BUSINESS Big 4 Drug Wholesalers Raided on Bid-Rigging Charges
November 28, 2019
-
REGULATORY Japan’s First Biosimilars of Avastin, Nesp, Forteo Receive Listing
November 27, 2019
-
BUSINESS Asahi Kasei to Buy Veloxis for 143.2 Billion Yen, Eyes US Transplant Market
November 26, 2019
-
REGULATORY MOF Panel Leery of Pricey Drugs for Huge Patient Population: FY2020 Budget Recommendation
November 26, 2019
-
REGULATORY Xolair’s Pollen Allergy Nod Delayed as Novartis Says It Needs More Time to Prepare for Launch
November 25, 2019
-
REGULATORY MHLW Wants to Ease Unfairness Concerns by Adding New Innovation Gauge to PMP Company Criteria
November 25, 2019
-
COMMENTARY Unison Capital Shows Rising Presence with Kyowa Deal, PE Fund Potential Catalyst for Industry Shakeup?
November 22, 2019
-
BUSINESS Evenity Debut, Copycat Entries Set to Jolt Power Map of Japan Osteoporosis Market
November 21, 2019
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…